HomepageHXB • FRA
add
Hemispherx Biopharma
Vorige slotkoers
€ 6,10
Jaar-range
€ 6,10 - € 22,00
Beurswaarde
3,97Â mln. USD
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 21,00K | -53,33% |
Bedrijfskosten | 2,93Â mln. | -50,23% |
Netto inkomsten | -4,18Â mln. | 30,03% |
Netto winstmarge | -19,88K | -49,93% |
Winst per aandeel | -0,44 | 95,60% |
EBITDA | -2,91Â mln. | 49,77% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 3,05Â mln. | -23,38% |
Totale activa | 5,78Â mln. | -32,83% |
Totale passiva | 15,56Â mln. | 56,75% |
Totaal aandelenvermogen | -9,78 mln. | — |
Uitstaande aandelen | 8,15 mln. | — |
Koers-boekwaardeverhouding | -1,91 | — |
Rendement op activa | -130,90% | — |
Rendement op kapitaal | 171,11% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -4,18Â mln. | 30,03% |
Operationele kasstroom | -1,99Â mln. | 49,79% |
Kasstroom uit beleggingen | -95,00K | -102,56% |
Kasstroom uit financiering | 2,72Â mln. | 162,20% |
Nettomutatie in liquide middelen | 638,00K | -18,83% |
Vrije kasstroom | -1,43Â mln. | 74,40% |
Over
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Opgericht
1966
Hoofdvestiging
Website
Werknemers
20
